In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40mg/m(2) on day 1) and vinorelbine (20mg/m(2) on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed ( four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.
|Titolo:||Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer|
|Data di pubblicazione:||2003|
|Appare nelle tipologie:||1.1 Articolo in rivista|